Skip to main content
. Author manuscript; available in PMC: 2012 Feb 7.
Published in final edited form as: Cancer Res. 2010 Jun 1;70(13):5281–5292. doi: 10.1158/0008-5472.CAN-10-0704

Figure 6. Periostin expression is dependent upon EGFR signaling and mutant p53 activation.

Figure 6

(A) Western blot analysis of periostin (90kDa) in EPC2-hTERT-EGFR-p53R175H, EPC2-hTERT-puro-neo, EPC2-hTERT-EGFR-neo and EPC2-hTERT-neo-p53R175H cells.

(B) Western blot analysis of periostin expression in EPC2-hTERT-EGFR-p53R175H cell lysates after 24h treatment with EGF (10ng/μl), EGFR inhibitior AG1478 (1 μM) and 5-iminodaunorubicin (3 μM). Immunoblotting for total EGFR and phosphorylated EGFR to confirm inhibition of EGFR as well as p21 to indicate restoration of wildtype p53 signaling. β-actin was used as a loading control. Densitometry ratios of periostin/β-actin were calculated and recorded.